Malenka Robert C. 4
4 · MapLight Therapeutics, Inc. · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) Director Robert Malenka Sells 34,398 Shares
What Happened
- Robert C. Malenka, a director of MapLight Therapeutics, sold a total of 34,398 shares of common stock in open-market transactions between Jan 28–30, 2026 for aggregate proceeds of approximately $635,857. Individual reported disposals:
- 5,860 shares at $18.61 each — $109,055 (Jan 28)
- 664 shares at $19.05 each — $12,649 (Jan 28)
- 21,262 shares at $18.55 each — $394,410 (Jan 29)
- 6,612 shares at $18.11 each — $119,743 (Jan 30)
- These were sales (code S), not purchases. According to the filing, the sales were made to cover tax obligations in connection with the settlement of restricted stock units (RSUs), a routine tax-withholding sale following an award.
Key Details
- Dates and prices: Jan 28–30, 2026; reported prices are weighted averages across multiple trades. The filing discloses trade price ranges and says the reporter can provide a per-trade breakdown on request.
- Total sold: 34,398 shares for ~$635,857.
- Reason: Footnote states shares were sold to cover tax withholding on settled RSUs.
- Holdings: The filing notes the shares are held by the Robert C. Malenka Living Trust (he is sole trustee and has voting/dispositive power). The exact number of shares owned after the transactions is not specified in the summary provided.
- Lock-up: Footnote indicates retained securities remain subject to an IPO lock-up agreement (180 days from Oct 26, 2025) with certain exceptions — the tax-withholding sale is noted in the filing.
- Timeliness: Form 4 was filed Jan 30, 2026 for transactions dated Jan 28–30; this appears within the typical two-business-day reporting window.
Context
- These sales are described as tax-withholding related to RSU settlement, which is a common, routine reason insiders sell shares and does not necessarily signal a change in their view of the company. Sales (S) are generally less informative about insider sentiment than purchases.
Insider Transaction Report
Form 4
Malenka Robert C.
Director
Transactions
- Sale
Voting Common Stock
[F1][F2]2026-01-28$18.61/sh−5,860$109,055→ 393,811 total - Sale
Voting Common Stock
[F1][F3]2026-01-28$19.05/sh−664$12,649→ 393,147 total - Sale
Voting Common Stock
[F1][F4]2026-01-29$18.55/sh−21,262$394,410→ 371,885 total - Sale
Voting Common Stock
[F1][F5]2026-01-30$18.11/sh−6,612$119,743→ 365,273 total
Holdings
- 31,672(indirect: See footnote)
Voting Common Stock
[F6]
Footnotes (6)
- [F1]Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $19.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.02 to $19.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.13 to $19.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-01-30